Zacks Investment Research cut shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) from a buy rating to a hold rating in a report issued on Wednesday morning.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Several other equities analysts have also recently weighed in on the company. Griffin Securities reiterated a buy rating and issued a $21.00 price target on shares of Ziopharm Oncology in a research report on Monday, August 15th. Wells Fargo & Co. upgraded Ziopharm Oncology from an underperform rating to a market perform rating in a research report on Wednesday, August 10th. Finally, Mizuho reiterated a neutral rating and issued a $5.00 price target (down from $7.00) on shares of Ziopharm Oncology in a research report on Monday, July 18th. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Ziopharm Oncology has an average rating of Hold and an average target price of $9.75.
Shares of Ziopharm Oncology (NASDAQ:ZIOP) traded down 0.57% during midday trading on Wednesday, hitting $5.21. The stock had a trading volume of 215,482 shares. The firm’s 50-day moving average price is $5.44 and its 200-day moving average price is $6.29. The stock’s market cap is $679.88 million. Ziopharm Oncology has a 1-year low of $4.45 and a 1-year high of $14.93.
Ziopharm Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.90. The company earned $1.70 million during the quarter, compared to analysts’ expectations of $1.52 million. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. Ziopharm Oncology’s revenue for the quarter was up 525.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.11) earnings per share. Analysts forecast that Ziopharm Oncology will post ($1.34) earnings per share for the current year.
A number of large investors have recently bought and sold shares of the stock. Advisor Group Inc. purchased a new stake in shares of Ziopharm Oncology during the second quarter valued at about $105,000. Royal Bank of Canada raised its stake in shares of Ziopharm Oncology by 18.8% in the second quarter. Royal Bank of Canada now owns 19,235 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 3,046 shares during the period. Oppenheimer & Co. Inc. raised its stake in shares of Ziopharm Oncology by 4.8% in the second quarter. Oppenheimer & Co. Inc. now owns 20,100 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 919 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Ziopharm Oncology during the second quarter valued at about $114,000. Finally, Principal Financial Group Inc. raised its stake in shares of Ziopharm Oncology by 5.5% in the second quarter. Principal Financial Group Inc. now owns 21,388 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 1,124 shares during the period. 44.94% of the stock is owned by institutional investors.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.